[1] Melzer N,Ruck T,Fuhr P,et al.Clinical features,pathogenesis,and treatment of myasthenia gravis:A supplement to the guidelines of the german neurological society[J].J Neurol,2016,263(8):1473-1494 [2] Hendricks T M,Bhatti M T,Hodge D O,et al.Incidence,epidemiology,and transformation of ocular myasthenia gravis:A population-based study[J].Am J Ophthalmol,2019,205:99-105. [3] Dresser L,Wlodarski R,Rezania K,et al.Myasthenia gravis:Epidemiology,pathophysiology and clinical manifestations[J].J Clin Med,2021,10(11):2235. [4] He D,Zhou Y,Zhang Y,et al.Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis:A real-world case series[J].J Neuroimmunol,2025,401:578558. [5] Wong S H.Rating scale for ocular myasthenia gravis:A call to action![J].J Neuroophthalmol,2018,38(2):138. [6] Mao B,Wang R,Liu X,et al.Low-dose rituximab in AChR antibody-positive ocular myasthenia gravis:Efficacy and safety—a preliminary study[J].Medicine,2025,104(44):e45346. [7] Shuey N H.Ocular myasthenia gravis:A review and practical guide for clinicians[J].Clin Exp Optom,2022,105(2):205-213. [8] 中华医学会眼科学分会神经眼科学组《中国眼肌型重症肌无力临床诊疗专家共识》专家组.中国眼肌型重症肌无力临床诊疗专家共识(2025)[J].中华眼底病杂志,2025,41(12):907-921. Expert Workgroup of Chinese Expert Consensus on the Clinical Diagnosis and Management of Ocular Myasthenia Gravis(2025),Neuro-Ophthalmology Group of Ophthalmology Branch of Chinese Medical Association,Neuro-Ophthalmology Society of Chinese Research Hospital Association.Chinese expert consensus on the clinical diagnosis and management of ocular myasthenia gravis(2025)[J].Chin J Ocul Fundus Dis,2025,41(12):907-921. [9] 中华医学会神经病学分会神经免疫学组.中国重症肌无力诊断和治疗指南(2025版)[J].中华神经科杂志,2025,58:721-741. Neuroimmunology Group,Neurology Branch of Chinese Medical Association.Guidelines for the diagnosis and treatment of myasthenia gravis in China(2025 edition)[J].Chinese Journal of Neurology,2025,58:721-741 [10] Aguirre F,Manin A,Fernandez V C,et al.C3,C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis[J].Ther Adv Neurol Disord,2020,13:1756286420935697. [11] Wang L,Wang S,Yang H,et al.No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis:A systematic retrospective study involving 67 patients[J].Brain Behav,2021,11(7):e02203. [12] Ching J,Richards D,Lewis R A,et al.Myasthenia gravis exacerbation in association with antibody overshoot following plasmapheresis[J].Muscle Nerve,2021,64(4):483-487. [13] Koneczny I,Mané-Damas M,Zong S,et al.A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression[J].Front Immunol,2024,15:1325171. [14] Claytor B,Li Y.Challenges in diagnosing coexisting ocular myasthenia gravis and thyroid eye disease[J].Muscle Nerve,2021,63(5):631-639. [15] Abraham A,Breiner A,Barnett C,et al.The utility of a single simple question in the evaluation of patients with myasthenia gravis[J].Muscle Nerve,2018,57(2):240-244. [16] Dewilde S,Janssen M F,Tollenaar N H,et al.Concordance between patient-and physician-reported myasthenia gravis activities of daily living(MG-ADL)scores[J].Muscle Nerve,2023,68(1):65-72. [17] Wong S H,Abuzaitoun R,Cornblath W T,et al.Multicenter validation of the ocular myasthenia gravis rating scale questionnaire[J].Neurology,2025,104(1):e210150. [18] Zhou L Y,Su C,Liu T J,et al.Validity and reliability of the ocular motor nerve palsy scale[J].Neural Regen Res,2018,13(10):1851-1856. [19] Fan Y F,Tu S J,Liu Y,et al.Investigation of the differential susceptibility of extraocular muscles in patients diagnosed with ocular myasthenia gravis based on the computerized diplopia test and the ocular motor nerve palsy scale[J].Front Neurol,2024,15:1353248. [20] Keene K R,de Nie J M,Brink M J,et al.Diagnosing myasthenia gravis using orthoptic measurements:Assessing extraocular muscle fatiguability[J].J Neurol Neurosurg Psychiatry,2023,94(2):151-151. [21] Velonakis G,Papadopoulos V E,Karavasilis E,et al.MRI evidence of extraocular muscle atrophy and fatty replacement in myasthenia gravis[J].Neuroradiology,2021,63(9):1531-1538. [22] Zhou Q,Zhao X,Wang M,et al.Combined use of magnetization transfer ratio and T2-mapping to evaluate extraocular muscle pathophysiology in myasthenia gravis with ophthalmoparesis[J].Int J Med Sci,2024,21(14):2799-2806. [23] Lueangaram S,Tritanon O,Siriyotha S,et al.Radiological characteristics of extraocular muscles in myasthenia gravis patients with ocular manifestations:A case-control study[J].Clin Ophthalmol,2021,15:2279-2285. [24] Keene K R,Notting I C,Verschuuren J J G M,et al.Eye muscle MRI in myasthenia gravis and other neuromuscular disorders[J].J Neuromuscul Dis,2023,10(5):869-883. [25] Chen P,Zhou Q,Zhao X,et al.Extraocular muscle volume on time-of-flight magnetic resonance angiography in patients with myasthenia gravis[J].Muscle Nerve,2024,70(3):379-386. [26] Zhang M,Zhang X,Huang Q,et al.Apparent diffusion coefficient:A predictor of the efficacy of glucocorticoid therapy in active moderate-severe thyroid eye disease:A retrospective cohort study[J].BMC Endocr Disord,2025,25(1):177. [27] Song X,Tong W,Lei C,et al.A clinical decision model based on machine learning for ptosis[J].BMC Ophthalmol,2021,21(1):169. [28] Khalili Pour E,Mahmoudi T,Ahmadzadeh H,et al.Quantitative analysis of the eyelid curvature in patients with blepharoptosis[J].BMC Med Imaging,2024,24(1):97. [29] Chen H C,Tzeng S S,Hsiao Y C,et al.Smartphone-based artificial intelligence-assisted prediction for eyelid measurements:Algorithm development and observational validation study[J].JMIR Mhealth Uhealth,2021,9(10):e32444. [30] Lootus M,Beatson L,Atwood L,et al.Development and assessment of an artificial intelligence-based tool for ptosis measurement in adult myasthenia gravis patients using selfie video clips recorded on smartphones[J].Digit Biomark,2023,7(1):63-73. [31] Liu N,Liang G,Li L,et al.An eyelid parameters auto-measuring method based on 3D scanning[J].Displays,2021,69:102063. [32] Nam Y,Song T,Lee J,et al.Development of a neural network-based automated eyelid measurement system[J].Sci Rep,2024,14(1):1202. [33] DeAngelis K D,Rider A,Potter W,et al.Eyelid spontaneous blink analysis and age-related changes through high-speed imaging[J].Ophthalmic Plast Reconstr Surg,2019,35(5):487-490. [34] Sanchis-Jurado V,Talens-Estarelles C,Esteve-Taboada J J,et al.Non-invasive high-speed blinking kinematics characterization[J].Graefes Arch Clin Exp Ophthalmol,2020,258(12):2701-2714. [35] Nguyen T T,Kang J J,Chae J H,et al.Oculomotor fatigability with decrements of saccade and smooth pursuit for diagnosis of myasthenia gravis[J].J Neurol,2023,270(5):2743-2755. [36] Chae J,Nguyen T T,Oh S Y.Quantification of saccadic fatigability and diagnostic efficacy for myasthenia gravis[J].J Neurol,2024,271(8):5035-5045. [37] Nguyen E M N L,Clough M J,Fielding J,et al.A video-oculography study of fixation instability in myasthenia gravis[J].Front Neurol,2025,16:1493418. [38] Chisari C G,Sciacca G,Reggio E,et al.Subclinical involvement of eye movements detected by video-based eye tracking in myasthenia gravis[J].Neurol Sci,2023,44(7):2555-2559. [39] Tseng R M W W,Tham Y C,Rim T H,et al.Emergence of non-artificial intelligence digital health innovations in ophthalmology:A systematic review[J].Clin Exp Ophthalmol,2021,49(7):741-756. [40] Yu B,Li Y H,Li Y L,et al.Enhanced diplopia detection and binocular single vision assessment through virtual reality:A comprehensive study[J].Sci Rep,2025,15(1):8355. [41] Garbey M,Joerger G,Lesport Q,et al.A digital telehealth system to compute myasthenia gravis core examination metrics:Exploratory cohort study[J].JMIR Neurotechnol,2023,2:e43387. [42] Garbey M,Lesport Q,Girma H,et al.Application of digital tools and artificial intelligence in the myasthenia gravis core examination[J].Front Neurol,2024,15:1474884. [43] Li J,Zhu C,Zhao M,et al.OMGMed:Advanced system for ocular myasthenia gravis diagnosis via eye image segmentation[J].Bioengineering,2024,11(6):595. [44] Zhu H,Yang H,Xu S,et al.Frequency-encoded eye tracking smart contact lens for human-machine interaction[J].Nat Commun,2024,15(1):3588. [45] Schärer N,Villani F,Melatur A,et al.ElectraSight:Smart glasses with fully onboard non-invasive eye tracking using hybrid contact and contactless EOG[A/OL].arXiv:2412.14848.https://doi.org/10.485501/arXiv:2412.14848. [46] Kim J,Salvatore G A,Araki H,et al.Battery-free,stretchable optoelectronic systems for wireless optical characterization of the skin[J].Sci Adv,2016,2(8):e1600418. [47] Ruzhansky K,Li Y B,Wolfe G I,et al.Standardization of myasthenia gravis outcome measures in clinical practice:A report of the MGFA task force[J].Muscle Nerve,2025,72(1):56-65. [48] Leube A,Rifai K,Wahl S.Sampling rate influences saccade detection in mobile eye tracking of a reading task[J].J Eye Mov Res,2017,10(3):1-11. [49] Parker T M,Badihian S,Hassoon A,et al.Eye and head movement recordings using smartphones for telemedicine applications:Measurements of accuracy and precision.[J].Front Neurol,2022,13:789581. [50] 韩遵海,尹颖,何茵,等.重症肌无力日常生活能力量表的汉化和信效度研究[J].中华现代护理杂志,2023,29(8):1046-1050. Han Z H,Yin Y,He Y,et al.Sinicization,reliability and validity of Activities of Daily Living Scale for myasthenia gravis[J].Chinese Journal of Modern Nursing,2023,29(8):1046-1050. |